Ignite Creation Date:
2025-12-25 @ 3:31 AM
Ignite Modification Date:
2026-03-09 @ 4:06 AM
Study NCT ID:
NCT05488405
Status:
COMPLETED
Last Update Posted:
2023-09-07
First Post:
2022-08-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Sponsor:
Dr. Falk Pharma GmbH
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SAV-1/EEA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None